

# Review of: "[Review Article] Independent Analysis of the Results of the First Infant Immunization Campaign with Beyfortus® (Nirsevimab, Monoclonal Antibody Against RSV Bronchiolitis Virus): Mixed Results, Identification of Biases, and Possible Role and Mechanisms of ADE (Antibody Dependent Enhancement)"

Riccardo Marino

Potential competing interests: No potential competing interests to declare.

I really appreciated the work, and I find it well done. For each concept, the source is correctly cited, and the reasoning is logical and clear. However, I would recommend, since no reference has been made to the PRISMA criteria for meta-analyses/reviews, describing the study as a "narrative review".

I also recommend not going into details about the prices of nirsevimab in different countries, but to focus just on the costs/benefits ratio.